Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
| ▸ | TYK2 | P29597 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.45 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103818 | 0.87 | KMT2A (0.50) | KMT2AMEN1GRIK1LMNAMAPT | |
| SCHEMBL4101401 | 0.83 | OXER1 (0.46) | SLC6A2 | |
| SCHEMBL4101409 | 0.81 | SLC6A2 (0.61) | KMT2AMEN1JAK2TYK2MDM2 | |
| SCHEMBL7610700 | 0.79 | SLC6A2 (0.62) | KMT2AMEN1JAK2JAK1TYK2 | |
| SCHEMBL4101233 | 0.79 | RAB9A (0.52) | KMT2AMEN1GRIK1LMNAKCNMA1 | |
| Maleic Acid SCHEMBL7616566 | 0.78 | SLC6A2 (0.53) | KMT2AMEN1GRIK1JAK2JAK1 | |
| Fumaric Acid SCHEMBL7616572 | 0.78 | SLC6A2 (0.53) | KMT2AMEN1GRIK1JAK2JAK1 | |
| SCHEMBL28614456 | 0.76 | CA12 (0.54) | KMT2AMEN1LMNAMAPTCNR1 | |
| SCHEMBL27777662 | 0.75 | OXER1 (0.43) | SLC6A2 | |
| SCHEMBL28980321 | 0.75 | OXER1 (0.43) | KMT2ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078716-A1 | New derivatives of 1H-indol-1-yl-urea, method for preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2009-07-15 | — | — | EP | disclosed |
| US-20090176794-A1 | 1H-INDOL-1-YL-UREA COMPOUNDS | LES LABORATOIRES SERVIER (FR) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176794-A1 | 1H-INDOL-1-YL-UREA COMPOUNDS | TPH1, HTR1D, IDO1 | KMT2A 2091/4885MEN1 2140/4885GRIK1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.